Claims for Patent: 11,737,983

Summary for Patent: 11,737,983

Title:	Storage stable sincalide formulations
Abstract:	Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging.
Inventor(s):	Srikanth Sundaram
Assignee:	Maia Pharmaceuticals Inc
Application Number:	US17/711,122
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,737,983
Patent Claims:	1. A solid composition comprising: (i) from about 1 to about 10 mcg of sincalide; (ii) from about 0.4 to about 4 mg of pentetic acid; (iii) from about 6 to about 45 mg of arginine hydrochloride; (iv) from about 0.5 to about 8 mg of L-methionine; (v) from about 3 to about 30 mg of L-lysine hydrochloride; (vi) from about 0.008 to about 1 mg of sodium metabisulfite; and (vii) from about 34 to about 340 mg of mannitol, wherein the solid composition comprises a pH of about 6.5 to about 7.5 when reconstituted in a pharmaceutically acceptable diluent, and wherein the solid composition does not contain phosphate buffer, a surfactant, a solubilizer, polysorbate 20, or polysorbate 80, wherein the solid composition contains less than 5% total impurities and has a sincalide level of at least 90% after 15 months of storage at 25° C. and 60% relative humidity. 2. The solid composition of claim 1, wherein the solid composition does not contain a buffer having a pKa within one unit of the pH. 3. The solid composition of claim 2, wherein the solid composition does not contain a buffer selected from the group consisting of phosphoric acid, citric acid, citrate, sulfosalicylate, acetic acid, acetate, methyl boronic acid, boronate, disodium succinate hexahydrate, lactic acid, lactate, maleic acid, maleate, potassium chloride, benzoic acid, sodium benzoate, carbonic acid, carbonate, bicarbonate, boric acid, sodium borate, sodium chloride, succinic acid, succinate, tartaric acid, tartrate, tris-(hydroxymethyl)aminomethane, N-2-hydroxyethylpiperazine, N′-2-ethanesulfonic acid, CHAPS, and any combination thereof. 4. The solid composition of claim 1, wherein the solid composition does not contain any polysorbate. 5. The solid composition of claim 1, wherein the solid composition is a lyophilized powder. 6. A method for the diagnosis of gall bladder and/or pancreatic disorders in a patient in need thereof comprising administering a diagnostically effective amount of the solid composition of claim 1 in reconstituted form to the patient. 7. The solid composition of claim 1, wherein the solid composition comprises: (i) about 5 mcg of sincalide; (ii) about 2 mg of pentetic acid; (iii) about 30 mg of arginine hydrochloride; (iv) about 4 mg of L-methionine; (v) about 15 mg of L-lysine hydrochloride; (vi) about 0.04 mg of sodium metabisulfite; and (viii) about 170 mg of mannitol. 8. The solid composition of claim 7, wherein the solid composition does not contain any polysorbate and/or wherein the solid composition does not contain a buffer having a pKa within one unit of the pH. 9. The solid composition of claim 7, wherein the solid composition is a lyophilized powder. 10. A vial comprising the solid composition of claim 7. 11. A method for the diagnosis of gall bladder and/or pancreatic disorders in a patient in need thereof comprising administering a diagnostically effective amount of the solid composition of claim 7 in reconstituted form to the patient. 12. The solid composition of claim 1, wherein the solid composition comprises: (i) from about 2.5 to about 10 mcg of sincalide; (ii) from about 1 to about 4 mg of pentetic acid; (iii) from about 15 to about 45 mg of arginine hydrochloride; (iv) from about 2 to about 8 mg of L-methionine; (v) from about 7.5 to about 30 mg of L-lysine hydrochloride; (vi) from about 0.02 to about 1 mg of sodium metabisulfite; and (vii) from about 85 to about 340 mg of mannitol. 13. The solid composition of claim 12, wherein the solid composition does not contain any polysorbate and/or wherein the solid composition does not contain a buffer having a pKa within one unit of the pH. 14. The solid composition of claim 12, wherein the solid composition is a lyophilized powder. 15. A method for the diagnosis of gall bladder and/or pancreatic disorders in a patient in need thereof comprising administering a diagnostically effective amount of the solid composition of claim 12 in reconstituted form to the patient. 16. A vial comprising the solid composition of claim 12. 17. A vial comprising the solid composition of claim 1. 18. A kit comprising the vial of claim 17 and a fluid portion. 19. A method of making the solid composition of claim 1, the method comprising: (1) mixing: (i) sincalide, (ii) pentetic acid, (iii) arginine hydrochloride, (iv) L-methionine, (v) L-lysine hydrochloride, (vi) sodium metabisulfite, (vii) mannitol, (viii) a pH adjuster, and (ix) water; and (2) lyophilizing the mixture.